HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sandler, E. D. Articles by Hattner, R. S. Search for Related Content PubMed PubMed Citation Articles by Sandler, E. D. Articles by Hattner, R. S.

Duration of Etidronate Effect Demonstrated by Serial Bone Scintigraphy

Departments of Radiology and Nuclear Medicine, UCSF, San Francisco, California

Correspondence: For reprints contact: E. Dayan Sandler, MD, Chief Resident, Nuclear Medicine, Department of Radiology, University of California, San Francisco, CA 94143-0252.

ABSTRACT

There have been several reports of etidronate disodium (EHDP) interference upon the biodistribution of ^99mTc-methylene diphosphonate (MDP). With the increasing use of etidronate for the treatment of Paget's disease, hypercalcemia, and osteoporosis, nuclear physicians can expect to encounter increasing numbers of cases in which EHDP-induced artifacts impair the diagnostic utility of bone scans. The temporal duration of this effect is unknown yet obviously important. We report serial bone scintigraphy in a patient who received a single dose of EHDP for hypercalcemia. Normal biodistribution of ^99mTc-MDP was noted at 15 days, suggesting that 2 wk are sufficient before performing a bone scan after a single intravenous dose of etidronate.

This article has been cited by other articles:

				J. Installe, A. Nzeusseu, A. Bol, G. Depresseux, J.-P. Devogelaer, and M. Lonneux 18F-Fluoride PET for Monitoring Therapeutic Response in Paget's Disease of Bone J. Nucl. Med., October 1, 2005; 46(10): 1650 - 1658. [Abstract] [Full Text] [PDF]

				N. Pandit-Taskar, M. Batraki, and C. R. Divgi Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases J. Nucl. Med., August 1, 2004; 45(8): 1358 - 1365. [Abstract] [Full Text] [PDF]

				J. A. Carrasquillo, M. Whatley, V. Dyer, W. D. Figg, and W. Dahut Alendronate Does Not Interfere with 99mTc-Methylene Diphosphonate Bone Scanning J. Nucl. Med., September 1, 2001; 42(9): 1359 - 1363. [Abstract] [Full Text] [PDF]